PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 3.50 ▲ 0.01 (0.29%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Amneal Pharmaceuticals Inc | AMRX | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.49 | 3.56 | 3.40 | 3.42 | 3.49 | 20:00:00 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,960 | 1,300,655 | $ 3.49 | $ 4,533,332 | 2,174,509 | 2.27 - 24.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:30:00 | 105,671 | $ 3.49 | USD |
Amneal Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.04B | 299.09M | $ -20.92M | -0.16 | -6.43 | 298.05M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 7.87M | $ - | 0.00% | 5.00 | 0.30% |
Amneal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/11/2019 | 17:15 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 9/10/2019 | 12:14 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 9/05/2019 | 09:25 | Business Wire | Amneal Announces Approval of Generic Version of Amicar® |
| 9/03/2019 | 08:35 | Business Wire | Amneal Pharmaceuticals to Present at the Morgan Stanley 17th.. |
| 8/28/2019 | 16:54 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/26/2019 | 17:28 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 8/26/2019 | 17:28 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.73 | 4.08 | 2.65 | 3.2864 | 3M | 0.76 | 27.84% |
| 1 Month | 2.41 | 4.08 | 2.27 | 2.8786 | 2M | 1.08 | 44.81% |
| 3 Months | 6.86 | 7.48 | 2.27 | 3.6347 | 2M | -3.37 | -49.13% |
| 6 Months | 12.72 | 14.79 | 2.27 | 6.2474 | 2M | -9.23 | -72.56% |
| 1 Year | 23.56 | 24.35 | 2.27 | 10.1502 | 1M | -20.07 | -85.19% |
| 3 Years | 17 | 24.48 | 2.27 | 12.2780 | 1M | -13.51 | -79.47% |
| 5 Years | 17 | 24.48 | 2.27 | 12.2780 | 1M | -13.51 | -79.47% |
Amneal Pharmaceuticals Description
| Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment. |
